SAVI 双 (™) 偏头痛治疗
K号: K230358 · 2023-05-16
广告
申请人Eneura, Inc.
决定日期2023-05-16
产品代码OKP
咨询委员会NE
请注意，您提供的文本“NE”不足以进行翻译，因为它不是一个完整的句子或描述。请提供完整的医疗设备监管文本，以便我能够进行准确的翻译。
决定实质等同
器械摘要
SAVI Dual (TM) Migraine Therapy is the device name listed in this FDA 510(k) record. The listed applicant is Eneura, Inc.. It received FDA 510(k) clearance on 2023-05-16 under 510(k) number K230358. The device is classified under product code OKP. It was reviewed by the NE advisory panel. FDA Decision: Substantially Equivalent.
常见问题
What is the SAVI Dual (TM) Migraine Therapy?
SAVI Dual (TM) Migraine Therapy is a medical device that received FDA 510(k) clearance on 2023-05-16. The listed applicant is Eneura, Inc.. The 510(k) number is K230358.
When did SAVI Dual (TM) Migraine Therapy receive FDA 510(k) clearance?
SAVI Dual (TM) Migraine Therapy received FDA 510(k) clearance on 2023-05-16, under 510(k) number K230358.
Who is the listed applicant for SAVI Dual (TM) Migraine Therapy?
The FDA 510(k) record lists Eneura, Inc. as the applicant. This does not by itself establish the device manufacturer.
What is the FDA product code for SAVI Dual (TM) Migraine Therapy?
The FDA product code for SAVI Dual (TM) Migraine Therapy is OKP.
相关临床试验
关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系；请查阅链接的官方来源。
列明Eneura, Inc.为申报人的其他记录
关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系；请查阅链接的官方来源。
相关器械（代码：OKP）
关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系；请查阅链接的官方来源。
官方来源
在 FDA 数据库中查看 →数据来源于FDA开放API。如需最新且权威的信息，请务必参考官方记录。
广告